14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of TGTX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

TG Therapeutics stock price down 1.89% on Wednesday
(Updated on Apr 24, 2024)

Sell candidate since Apr 19, 2024 Gain 1.45% PDF

The TG Therapeutics stock price fell by -1.89% on the last day (Wednesday, 24th Apr 2024) from $14.25 to $13.98. During the last trading day the stock fluctuated 4.41% from a day low at $13.74 to a day high of $14.35. The price has fallen in 6 of the last 10 days and is down by -4.96% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -513 thousand shares and in total, 3 million shares were bought and sold for approximately $37.76 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -6.48% during the next 3 months and, with a 90% probability hold a price between $11.37 and $16.42 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

TGTX Signals & Forecast

There are mixed signals in the stock today. The TG Therapeutics stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $13.99 and $15.09. A break-up above any of these levels will issue buy signals. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements. A buy signal was issued from a pivot bottom point on Friday, April 19, 2024, and so far it has risen 1.45%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for TG Therapeutics stock

TG Therapeutics finds support from accumulated volume at $13.93 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.607 between high and low, or 4.41%. For the last week, the stock has had daily average volatility of 4.66%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (TGTX) For The Upcoming Trading Day Of Thursday 25th

For the upcoming trading day on Thursday, 25th we expect TG Therapeutics to open at $14.02, and during the day (based on 14 day Average True Range), to move between $13.33 and $14.63, which gives a possible trading interval of +/-$0.649 (+/-4.65%) up or down from last closing price. If TG Therapeutics takes out the full calculated possible swing range there will be an estimated 9.29% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $13.93 (0.36%) than the resistance at $15.31 (9.51%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is TG Therapeutics stock A Buy?

TG Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.424 Sell Candidate Unchanged

Predicted Opening Price for TG Therapeutics of Thursday, April 25, 2024

Fair opening price April 25, 2024 Current price
$14.02 ( 0.302%) $13.98

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for TGTX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 14.63 4.64 %
R2 14.40 2.98 %
R1 14.25 1.96 %
Current price: 13.98
Support S1 13.79 -1.36 %
S2 13.65 -2.38 %
S3 13.42 -4.04 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 17.22 23.18 %
R2 15.80 13.02 %
R1 15.31 9.51 %
Current price 13.98
Support S1 13.93 -0.358%
S2 13.91 -0.501%
S3 13.36 -4.43%

FAQ

What is the symbol for TG Therapeutics Stock and on which exchange is it traded?
The symbol for TG Therapeutics is TGTX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell TG Therapeutics Stock?
TG Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

How to buy TG Therapeutics Stock?
TG Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy TG Therapeutics Stock.

What's the current price of TG Therapeutics Stock?
As of the end of day on the Apr 24, 2024, the price of an TG Therapeutics (TGTX) share was $13.98.

What is the 52-week high and low for TG Therapeutics Stock?
The 52-week high for TG Therapeutics Stock is $35.67 and the 52-week low is $6.47.

What is the market capitalization of TG Therapeutics Stock?
As of the Apr 24, 2024, the market capitalization of TG Therapeutics is 2.202B.

When is the next earnings date for TG Therapeutics?
The upcoming earnings date for TG Therapeutics is May 06, 2024.
Click to get the best stock tips daily for free!

About TG Therapeutics

TG Therapeutics TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra... TGTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT